Investment groups & corporate VCs for process and crystallization startups
A short, evidence-qualified list of venture and corporate investors whose official pages show process, manufacturing or enabling-technology relevance — for researchers moving from grants or consortia into a company or spin-out. Informational only; not exhaustive and not an endorsement.
The Grant Lattice is independent. This list is informational and compiled from public sources. Inclusion does not constitute an endorsement, recommendation, introduction or affiliation. We are not affiliated with any firm listed. Always confirm current investment focus, stage and contact details on the firm’s official website. The investor always has the final word.
Equity is not a grant. Venture and corporate venture capital usually buy company shares. That can mean ownership, board rights and dilution for founders. Grants and many consortia awards are non-dilutive. This site does not give financial, legal or fundraising advice.
University IP and confidentiality. Spin-outs normally need a licence or assignment through the university’s technology-transfer office. Do not send unpublished data, manuscripts or confidential invention details through public tip forms or unsolicited inboxes. Use only published approach routes on the firm’s own site.
Most crystallization hardware still starts elsewhere. SBIR/STTR, strategic partnerships and consortia are often the nearer step than large therapeutics-focused VCs. We omit big-name life-science firms unless official pages show process or manufacturing relevance.
Evidence limits. A named portfolio company or past manufacturing deal is historical context. It does not prove open applications, current check size, stage preference or interest in your technology. Always re-check the official site.
Corporate venture armNetherlands (Amsterdam HQ), Germany, Israel, United States
Type
Corporate venture arm (Merck KGaA, Darmstadt, Germany)
Typical stage (as published)
Seed through early-stage (company creation and early syndicated rounds as stated by Merck KGaA partnering pages); later rounds occur in the published portfolio
Primary focus
Biotechnology (healthcare and life-science tools) and technology (electronics, frontier technology and sustainability)
Process / manufacturing proof
Enabling tools and manufacturing platforms (official remit + named portfolio cases). Official site states a Biotechnology remit covering "disruptive tools and technologies for R&D as well as manufacturing" and a Life Science portfolio heading "Boost R&D and manufacturing". Named portfolio examples include Astraveus (automated end-to-end cGMP cell manufacturing platform) and CellFE (microfluidics for cell-therapy manufacturing). These are enabling-technology / manufacturing-tool cases, not crystallization-hardware specialists; they support process relevance without claiming open crystallization deal appetite.
Published approach route
Published contact email. Published contact page lists offices and the email info@m-ventures.com. No open application portal or check-size schedule was published on the pages checked.
Reading notes
Portfolio and contact pages are public; inclusion does not mean they are seeking crystallization deals now.
Verify current focus and contact details on the official site before any outreach.
Sources checked
M Ventures home — Biotechnology remit — “Targeting some of the most challenging disease and disruptive tools and technologies for R&D as well as manufacturing” (checked 05 Nov 2026)
The Grant Lattice is independent. This list is informational and compiled from public sources. Inclusion does not constitute an endorsement, recommendation, introduction or affiliation. We are not affiliated with any firm listed. Always confirm current investment focus, stage and contact details on the firm’s official website. The investor always has the final word.
Independent growth / private-equity style life-sciences investorUnited States (Raleigh, North Carolina HQ); North American companies stated as a target
Type
Independent growth / private-equity style life-sciences investor (Kineticos Capital Partners Fund Series)
Typical stage (as published)
Revenue-generating through lower mid-market (officially targets companies from revenue-generating up to about $10M EBITDA); North American focus. Not a typical university seed / company-creation fund.
Primary focus
Specialized pharma services, tools and equipment; also separate Kineticos funds for therapeutics and antimicrobial resistance
Process / manufacturing proof
Pharma tools/equipment mandate + named continuous-manufacturing equipment portfolio case (DIANT). Official Capital Partners pages state investment in "specialized pharma services, tools and equipment companies", with an Equipment focus area. The Kineticos portfolio page describes DIANT Pharma as an equipment company with continuous manufacturing technology for lipid nanoparticles and other nanoparticles. That is a named continuous-manufacturing equipment case. It is historical/portfolio evidence of process-equipment interest, not a promise of open applications or crystallization-specific checks.
Published approach route
Published contact page (no email found). Published contact page invites parties looking for a growth partner to reach out and lists the Raleigh office address. No public email address or open intake form was found on that contact page when checked.
Reading notes
Stage fit is later than many academic spin-outs; non-dilutive SBIR/STTR or consortia routes often come first.
DIANT is a portfolio example only; it does not prove current crystallization-hardware interest or open applications.
Kineticos home — “invests in life science companies, including outsourced pharma, tools and equipment” (checked 05 Nov 2026)
Kineticos portfolio — DIANT — “DIANT is an equipment company with a continuous manufacturing technology for Lipid Nanoparticles (“LNP”) and nanoparticle drug product development.” (checked 05 Nov 2026)
Kineticos contact — “If you are looking for a growth partner, please reach out to us today.” (checked 05 Nov 2026)
The Grant Lattice is independent. This list is informational and compiled from public sources. Inclusion does not constitute an endorsement, recommendation, introduction or affiliation. We are not affiliated with any firm listed. Always confirm current investment focus, stage and contact details on the firm’s official website. The investor always has the final word.
Other pathways that often come first
Non-dilutive or precompetitive routes are frequently closer for process and crystallization work:
Suggest an addition or correction (public official URL only; no confidential material): Suggest a tip · site Suggest a call form · footer Feedback. We verify tips on official pages before listing them.
The Grant Lattice is independent. This list is informational and compiled from public sources. Inclusion does not constitute an endorsement, recommendation, introduction or affiliation. We are not affiliated with any firm listed. Always confirm current investment focus, stage and contact details on the firm’s official website. The investor always has the final word. Page generated 12 Nov 2026; each card shows its own checked date.